Experts say industry should use the opportunity provided in recent guidance to volunteer information for the US Food and Drug Administration to use in lieu of site inspections it cannot conduct due to the coronavirus pandemic.
The idea is that new types of information could help persuade the agency to approve applications without inspecting manufacturing sites...







